NCT00431236 - A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy | Biotech Hunter

Enrollment

810

Participants

Timeline

Start Date

November 6, 2006

Primary Completion Date

October 9, 2007

Study Completion Date

October 9, 2007

Conditions

Nausea and Vomiting, Chemotherapy-Induced

Interventions

DRUG

Oral Casopitant (GW679769)

DRUG

IV Casopitant (GW679769)

DRUG

IV ondansetron hydrochloride

DRUG

Oral dexamethasone

Trial Locations (80)

9

GSK Investigational Site, Dublin

24

GSK Investigational Site, Tallaght, Dublin

333

GSK Investigational Site, TaoYuan Hsien

404

GSK Investigational Site, Taichung

1000

GSK Investigational Site, Manila

1100

GSK Investigational Site, Quezon City

1529

GSK Investigational Site, Budapest

1590

GSK Investigational Site, Islamabad

1756

GSK Investigational Site, Sofia

2600

GSK Investigational Site, Baguio City, Benguet

2650

GSK Investigational Site, Edegem

3000

GSK Investigational Site, Leuven

3233

GSK Investigational Site, Mátraháza

4000

GSK Investigational Site, San Miguel de Tucumán

GSK Investigational Site, Liège

8000

GSK Investigational Site, Székesfehérvár

9010

GSK Investigational Site, Varna

10000

GSK Investigational Site, Zagreb

10400

GSK Investigational Site, Bangkok

11600

GSK Investigational Site, George Town

13122

GSK Investigational Site, Athens

15669

GSK Investigational Site, Papagos, Athens

16150

GSK Investigational Site, Kubang Kerian

20520

GSK Investigational Site, Turku

28035

GSK Investigational Site, Madrid

30008

GSK Investigational Site, Murcia

36280

GSK Investigational Site, Kangasala

40705

GSK Investigational Site, Taichung

46009

GSK Investigational Site, Valencia

50200

GSK Investigational Site, Chiang Mai

53400

GSK Investigational Site, Lahore

54000

GSK Investigational Site, Karachi

54600

GSK Investigational Site, Lahore

56124

GSK Investigational Site, Pisa

57010

GSK Investigational Site, Thessaloniki

61024

GSK Investigational Site, Kharkiv

65403

GSK Investigational Site, Kavala

65691

GSK Investigational Site, Brno

74800

GSK Investigational Site, Karachi

79031

GSK Investigational Site, Lviv

83024

GSK Investigational Site, Monteforte Irpino

88014

GSK Investigational Site, Uzhhorod

93586

GSK Investigational Site, Sarawak

95023

GSK Investigational Site, Sympheropol

300239

GSK Investigational Site, Timișoara

517507

GSK Investigational Site, Tirupati

682026

GSK Investigational Site, Kochi

700106

GSK Investigational Site, Iași

C1405CUB

GSK Investigational Site, Capital Federal

X5000JFK

GSK Investigational Site, Córdoba

S2000KZE

GSK Investigational Site, Rosario

10 000

GSK Investigational Site, Zagreb

Unknown

GSK Investigational Site, Zagreb

GSK Investigational Site, Wilton, Cork

625 00

GSK Investigational Site, Brno

586 01

GSK Investigational Site, Jihlava

708 52

GSK Investigational Site, Ostrava

150 06

GSK Investigational Site, Prague

390 19

GSK Investigational Site, Tábor

00029

GSK Investigational Site, Helsinki

564 29

GSK Investigational Site, Thessaloniki

00149

GSK Investigational Site, Rome

00184

GSK Investigational Site, Rome

07100

GSK Investigational Site, Sassari

15-540

GSK Investigational Site, Bialystok

85-796

GSK Investigational Site, Bydgoszcz

31-115

GSK Investigational Site, Krakow

10-357

GSK Investigational Site, Olsztyn

60-569

GSK Investigational Site, Poznan

61-866

GSK Investigational Site, Poznan

022328

GSK Investigational Site, Bucharest

975 17

GSK Investigational Site, Banská Bystrica

826 06

GSK Investigational Site, Bratislava

058 87

GSK Investigational Site, Poprad

120-752

GSK Investigational Site, Seoul

135-710

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Seoul

05071

GSK Investigational Site, Ávila

08916

GSK Investigational Site, Badalona

03115

GSK Investigational Site, Kyiv